Company Research
Whether you are exploring new sales opportunities or researching a new investment, FirstRain provides unique insight into important developments for Eli Lilly and Company (LLY). You can receive reports or configure the research engine for yourself.
Report On:
Eli Lilly and Company (LLY)
HEALTHCARE - Drugs - Drug Manufacturers - Major
Generated: Thursday September 15, 2011 04:15 AM
|
|
||||||||||||||||||
Quotes About Eli Lilly and Company
-
Home & Garden
The government has suggested that any teaching of our colleagues that is sponsored by anyone in the medical industry, such as pharmaceutical companies and equipment manufacturers, is suspect. It's considered almost a bribe, so the drug industry has cut back markedly on their teaching efforts,"
- Paul M. Packman -
Diabetes Drugs Byetta, Victoza Scrutinized For Possible Cancer Link
There are now several animal studies as well as clinical reports from humans that taken together raise concern that there may well be serious unexpected side effects of the GLP-1 class of drugs on the pancreas,"
- Peter Butler -
Eli Lilly charts out aggressive plan in anti-diabetes space
Lilly as a company is betting primarily on innovation and that's why we continue to plough back 20 per cent of our revenues in R&D,"
- Sandeep Gupta -
Eli Lilly launches NCD partnership program
NCDs in developing countries haven't garnered the same attention that TB, HIV/AIDS and malaria have. There are few successful models of treatment for NCDs and limited international funding,"
- Jacques Tapiero -
Pepsico, Coca Cola and Eli Lilly Adopt New Policies for Political Giving
This is a tremendous breakthrough,"
No Comment
-
Dollars for Docs database includes Fort Collins and Loveland doctors
Koehler, whose affiliation could not be determined Thursday, could not be reached for comment .
- Kathy Enyeart
-
Fewer Harvard faculty speak on pharma's behalf
Harvard Medical School recently instituted a new policy after congressional investigators found high-profile faculty had failed to disclose financial ties with pharma per university rules.
- Eric Campbell
-
Drug company speaking fees to Massachusetts doctors may be dropping
Kowal declined to be interviewed last week.
- Dr. Howard Grant
Latest Company Intelligence
-
Lilly's Open Screening Program: An Update
Corante | Sep 14,'11
I'm still at the RSC/SCI symposium in Cambridge, and a talk yesterday by Marta Pineiro-Nuñez gives me a chance to update this post about Eli Lilly's foray into opening up its screening to outside collaboration. That effort has been working away for the last two or three years, and the company is now revealing some details about how it's been going. -
Rep. Joe Walsh loses round in child support battle with former wife
Lynn Sweet - CHICAGO SUN-TIMES | Sep 14,'11
Rep. Joe Walsh (R-Ill.), a Tea Party leader, lost a round in a child support battle with his former wife on Wednesday. Chicago Sun-Times Abdon M. Pallasch reports that Cook County Circuit Court Judge Raul Vega issued a preliminary ruling ordering Walsh to explain why he appears to be $100,000 behind on his child-support payments. More from Pallasch: "Laura Walsh -- who works as a -
Lilly invests $30M in chronic-disease partnerships
Yahoo! Finance | Sep 13,'11
On Tuesday September 13, 2011, 3:46 pm INDIANAPOLIS (AP) -- Drugmaker Eli Lilly and Co. said Tuesday it will spend $30 million over five years to fight chronic illnesses like heart disease, diabetes, cancer and respiratory disease in developing countries. -
Lilly, Novo Diabetes Drugs Get Scrutiny on Possible Cancer Tie
Bloomberg.com | Sep 12,'11
Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (LLY) 's Byetta medicine and Novo Nordisk A/S's Victoza face scrutiny after some researchers warned that prolonged use of the insulin-raising treatments may make diabetics more vulnerable to cancers. -
Lilly, Amylin release new analysis of Bydureon
Yahoo! Finance | Sep 12,'11
On Monday September 12, 2011, 11:07 am INDIANAPOLIS (AP) -- Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday patients taking their potential once-weekly diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors like high blood pressure when compared to patients who received common diabetes treatments. -
Drug firm payments to doctors fall in Bay State
The BBJ's Morning Roundup - Bizjournals | Sep 8,'11
Payments to doctors for promoting pharmaceutical companies' products to their colleagues have dropped off significantly in Massachusetts last year, according to an analysis by The Boston Globe and ProPublica, a nonprofit online journalism organization. According to a report in the Globe, payments shelled out by Eli Lilly and Co. Eli Lilly and Co. Latest from The Business Journals Darvon,
FirstRain customers use intelligent business search to find actionable insights about companies, management, and industries. You can review company briefs, quickly research a new idea or opportunity, generate personalized industry reports, or set up alerts on reasons to call. Be sure to view our sample reports below.
